FDA Advisory Panel Votes to Add Peptides to Compounding List Despite Scientist Opposition

The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on Thursday to recommend adding the peptides BPC-157, KPV, TB-500, and MOTS-C to the list of substances that compounding pharmacies are permitted to produce. This decision went against the position of FDA scientists, who raised concerns about the lack of demonstrated clinical benefits and safety data for these peptides. The committee heard public comments and reviewed presentations from agency staff before making its recommendation. The vote marks a significant policy divergence within the FDA regarding the regulation of compounded peptide products.

First published Aug 4, 02:59 PM UTCUpdated Jul 23, 11:38 PM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 23, 11:38 PM UTCEditorial record as of Aug 4, 02:59 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

Opened from WirecurrentJul 23, 11:38 PM UTC

FDA Advisory Panel Votes to Add Peptides to Compounding List Despite Scientist Opposition

Coverage sources

External reporting used to assemble this Story.

FDA Advisory Panel Votes to Add Peptides to Compounding List Despite Scientist OppositionJust In NewsWesternJul 23, 11:38 PM UTC

Follow the context

Food and Drug Administration FDA